Company profile

Esperion Therapeutics

Lipid-lowering therapeutics

ESPR · NASDAQ · USA

Share price · ESPR

$3.18+1.13 (+55.12%) 3M

close as of 2026-07-14 · 24h delayed

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Bempedoic acid(Nexletol)
Approved
Undisclosed / early pipeline · ATP citrate lyaseSmall molecule
Atherosclerotic Cardiovascular Disease
Bempedoic acid/ezetimibe
Approved
ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Small molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.